

Cardiovascular Drugs Market [Indication: Hypertension, Hyperlipidemia, Coronary Artery Disease, Peripheral Artery Disease, Arrhythmia, and Others; Distribution Channel: Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy] - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Market Report | 2023-12-28 | 241 pages | Transparency Market Research

AVAILABLE LICENSES:

- Single User License \$5795.00
- Multi User License \$8795.00
- Global Site License \$11795.00

Report description:**Cardiovascular Drugs Market - Scope of Report**

TMR's report on the global Parkinson's disease therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Parkinson's disease therapeutics market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Parkinson's disease therapeutics market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Parkinson's disease therapeutics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Parkinson's disease therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Parkinson's

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

disease therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Parkinson's disease therapeutics market.

The report delves into the competitive landscape of the global Parkinson's disease therapeutics market. Key players operating in the global Parkinson's disease therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Parkinson's disease therapeutics market profiled in this report.

Key Questions Answered in Global Parkinson's disease therapeutics Market Report

- What is the sales/revenue generated by Parkinson's disease therapeutics across all regions during the forecast period?
- What are the opportunities in the global Parkinson's disease therapeutics market?
- What are the major drivers, restraints, opportunities, and threats in the market?
- Which regional market is set to expand at the fastest CAGR during the forecast period?
- Which segment is expected to generate the highest revenue globally in 2031?
- Which segment is projected to expand at the highest CAGR during the forecast period?
- What are the market positions of different companies operating in the global market?

Cardiovascular Drugs Market - Research Objectives and Research Approach

The comprehensive report on the global Parkinson's disease therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Parkinson's disease therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Parkinson's disease therapeutics market.

Table of Contents:

1. Preface
- 1.1. Market Definition and Scope
- 1.2. Market Segmentation
- 1.3. Key Research Objectives
- 1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Cardiovascular Drugs Market
4. Market Overview
 - 4.1. Introduction
 - 4.1.1. Product Definition
 - 4.1.2. Industry Evolution/Developments
- 4.2. Overview
- 4.3. Market Dynamics

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
- 4.4. Global Cardiovascular Drugs Market Analysis and Forecast, 2017-2031
- 5. Key Insights
- 5.1. Pipeline Analysis
- 5.2. Key Product/Brand Analysis
- 5.3. Key Mergers & Acquisitions
- 5.4. COVID-19 Pandemic Impact on Industry
- 6. Global Cardiovascular Drugs Market Analysis and Forecast, by Drug Class
- 6.1. Introduction & Definition
- 6.2. Key Findings/Developments
- 6.3. Market Value Forecast, by Drug Class, 2017-2031
- 6.3.1. Renin-Angiotensin System Blockers
 - 6.3.1.1. ACE Inhibitors
 - 6.3.1.2. Angiotensin Receptor Blockers
- 6.3.2. Beta Blockers
- 6.3.3. Diuretics
- 6.3.4. Anti-Clotting Agents
 - 6.3.4.1. Anti-Coagulants
 - 6.3.4.2. Platelet Aggregation Inhibitors
- 6.3.5. Antihyperlipidemics
- 6.3.6. Other Antihypertensive
- 6.3.7. Calcium Channel Blockers
- 6.3.8. Others
- 6.4. Market Attractiveness Analysis, by Drug Class
- 7. Global Cardiovascular Drugs Market Analysis and Forecast, by Indication
- 7.1. Introduction & Definition
- 7.2. Key Findings/Developments
- 7.3. Market Value Forecast, by Indication, 2017-2031
 - 7.3.1. Hypertension
 - 7.3.2. Hyperlipidemia
 - 7.3.3. Coronary Artery Disease
 - 7.3.4. Peripheral Artery Disease
 - 7.3.5. Arrhythmia
 - 7.3.6. Others
- 7.4. Market Attractiveness Analysis, by Indication
- 8. Global Cardiovascular Drugs Market Analysis and Forecast, by Distribution Channel
- 8.1. Introduction & Definition
- 8.2. Key Findings/Developments
- 8.3. Market Value Forecast, by Distribution Channel, 2017-2031
 - 8.3.1. Hospital Pharmacy
 - 8.3.2. Retail Pharmacy
 - 8.3.3. Online Pharmacy
- 8.4. Market Attractiveness Analysis, by Distribution Channel
- 9. Global Cardiovascular Drugs Market Analysis and Forecast, by Region
- 9.1. Key Findings

- 9.2. Market Value Forecast, by Region, 2017-2031
 - 9.2.1. North America
 - 9.2.2. Europe
 - 9.2.3. Asia Pacific
 - 9.2.4. Latin America
 - 9.2.5. Middle East & Africa
- 9.3. Market Attractiveness Analysis, by Region
- 10. North America Cardiovascular Drugs Market Analysis and Forecast
 - 10.1. Introduction
 - 10.2. Key Findings
 - 10.3. Market Value Forecast, by Drug Class, 2017-2031
 - 10.3.1. Renin-Angiotensin System Blockers
 - 10.3.1.1. ACE Inhibitors
 - 10.3.1.2. Angiotensin Receptor Blockers
 - 10.3.2. Beta Blockers
 - 10.3.3. Diuretics
 - 10.3.4. Anti-Clotting Agents
 - 10.3.4.1. Anti-Coagulants
 - 10.3.4.2. Platelet Aggregation Inhibitors
 - 10.3.5. Antihyperlipidemics
 - 10.3.6. Other Antihypertensive
 - 10.3.7. Calcium Channel Blockers
 - 10.3.8. Others
 - 10.4. Market Value Forecast, by Indication, 2017-2031
 - 10.4.1. Hypertension
 - 10.4.2. Hyperlipidemia
 - 10.4.3. Coronary Artery Disease
 - 10.4.4. Peripheral Artery Disease
 - 10.4.5. Arrhythmia
 - 10.4.6. Others
 - 10.5. Market Value Forecast, by Distribution Channel, 2017-2031
 - 10.5.1. Hospital Pharmacy
 - 10.5.2. Retail Pharmacy
 - 10.5.3. Online Pharmacy
 - 10.6. Market Value Forecast, by Country, 2017-2031
 - 10.6.1. U.S.
 - 10.6.2. Canada
 - 10.7. Market Attractiveness Analysis
 - 10.7.1. By Drug Class
 - 10.7.2. By Indication
 - 10.7.3. By Distribution Channel
 - 10.7.4. By Country
- 11. Europe Cardiovascular Drugs Market Analysis and Forecast
 - 11.1. Introduction
 - 11.2. Key Findings
 - 11.3. Market Value Forecast, by Drug Class, 2017-2031
 - 11.3.1. Renin-Angiotensin System Blockers

- 11.3.1.1. ACE Inhibitors
- 11.3.1.2. Angiotensin Receptor Blockers
- 11.3.2. Beta Blockers
- 11.3.3. Diuretics
- 11.3.4. Anti-Clotting Agents
 - 11.3.4.1. Anti-Coagulants
 - 11.3.4.2. Platelet Aggregation Inhibitors
- 11.3.5. Antihyperlipidemics
- 11.3.6. Other Antihypertensive
- 11.3.7. Calcium Channel Blockers
- 11.3.8. Others
- 11.4. Market Value Forecast, by Indication, 2017-2031
 - 11.4.1. Hypertension
 - 11.4.2. Hyperlipidemia
 - 11.4.3. Coronary Artery Disease
 - 11.4.4. Peripheral Artery Disease
 - 11.4.5. Arrhythmia
 - 11.4.6. Others
- 11.5. Market Value Forecast, by Distribution Channel, 2017-2031
 - 11.5.1. Hospital Pharmacy
 - 11.5.2. Retail Pharmacy
 - 11.5.3. Online Pharmacy
- 11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
 - 11.6.1. Germany
 - 11.6.2. U.K.
 - 11.6.3. France
 - 11.6.4. Italy
 - 11.6.5. Spain
 - 11.6.6. Rest of Europe
- 11.7. Market Attractiveness Analysis
 - 11.7.1. By Drug Class
 - 11.7.2. By Indication
 - 11.7.3. By Distribution Channel
 - 11.7.4. By Country/Sub-region
- 12. Asia Pacific Cardiovascular Drugs Market Analysis and Forecast
 - 12.1. Introduction
 - 12.2. Key Findings
 - 12.3. Market Value Forecast, by Drug Class, 2017-2031
 - 12.3.1. Renin-Angiotensin System Blockers
 - 12.3.1.1. ACE Inhibitors
 - 12.3.1.2. Angiotensin Receptor Blockers
 - 12.3.2. Beta Blockers
 - 12.3.3. Diuretics
 - 12.3.4. Anti-Clotting Agents
 - 12.3.4.1. Anti-Coagulants
 - 12.3.4.2. Platelet Aggregation Inhibitors
 - 12.3.5. Antihyperlipidemics

- 12.3.6. Other Antihypertensive
- 12.3.7. Calcium Channel Blockers
- 12.3.8. Others
- 12.4. Market Value Forecast, by Indication, 2017-2031
 - 12.4.1. Hypertension
 - 12.4.2. Hyperlipidemia
 - 12.4.3. Coronary Artery Disease
 - 12.4.4. Peripheral Artery Disease
 - 12.4.5. Arrhythmia
 - 12.4.6. Others
- 12.5. Market Value Forecast, by Distribution Channel, 2017-2031
 - 12.5.1. Hospital Pharmacy
 - 12.5.2. Retail Pharmacy
 - 12.5.3. Online Pharmacy
- 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
 - 12.6.1. China
 - 12.6.2. Japan
 - 12.6.3. India
 - 12.6.4. Australia & New Zealand
 - 12.6.5. Rest of Asia Pacific
- 12.7. Market Attractiveness Analysis
 - 12.7.1. By Drug Class
 - 12.7.2. By Indication
 - 12.7.3. By Distribution Channel
 - 12.7.4. By Country/Sub-region
- 13. Latin America Cardiovascular Drugs Market Analysis and Forecast
 - 13.1. Introduction
 - 13.2. Key Findings
 - 13.3. Market Value Forecast, by Drug Class, 2017-2031
 - 13.3.1. Renin-Angiotensin System Blockers
 - 13.3.1.1. ACE Inhibitors
 - 13.3.1.2. Angiotensin Receptor Blockers
 - 13.3.2. Beta Blockers
 - 13.3.3. Diuretics
 - 13.3.4. Anti-Clotting Agents
 - 13.3.4.1. Anti-Coagulants
 - 13.3.4.2. Platelet Aggregation Inhibitors
 - 13.3.5. Antihyperlipidemics
 - 13.3.6. Other Antihypertensive
 - 13.3.7. Calcium Channel Blockers
 - 13.3.8. Others
 - 13.4. Market Value Forecast, by Indication, 2017-2031
 - 13.4.1.1. Hypertension
 - 13.4.1.2. Hyperlipidemia
 - 13.4.1.3. Coronary Artery Disease
 - 13.4.1.4. Peripheral Artery Disease
 - 13.4.1.5. Arrhythmia

13.4.1.6. Others

13.5. Market Value Forecast, by Distribution Channel, 2017-2031

13.5.1. Hospital Pharmacy

13.5.2. Retail Pharmacy

13.5.3. Online Pharmacy

13.6. Market Value Forecast, by Country/Sub-region, 2017-2031

13.6.1. Brazil

13.6.2. Mexico

13.6.3. Rest of Latin America

13.7. Market Attractiveness Analysis

13.7.1. By Drug Class

13.7.2. By Indication

13.7.3. By Distribution Channel

13.7.4. By Country/Sub-region

14. Middle East & Africa Cardiovascular Drugs Market Analysis and Forecast

14.1. Introduction

14.2. Key Findings

14.3. Market Value Forecast, by Drug Class, 2017-2031

14.3.1. Renin-Angiotensin System Blockers

14.3.1.1. ACE Inhibitors

14.3.1.2. Angiotensin Receptor Blockers

14.3.2. Beta Blockers

14.3.3. Diuretics

14.3.4. Anti-Clotting Agents

14.3.4.1. Anti-Coagulants

14.3.4.2. Platelet Aggregation Inhibitors

14.3.5. Antihyperlipidemics

14.3.6. Other Antihypertensive

14.3.7. Calcium Channel Blockers

14.3.8. Others

14.4. Market Value Forecast, by Indication, 2017-2031

14.4.1. Hypertension

14.4.2. Hyperlipidemia

14.4.3. Coronary Artery Disease

14.4.4. Peripheral Artery Disease

14.4.5. Arrhythmia

14.4.6. Others

14.5. Market Value Forecast, by Distribution Channel, 2017-2031

14.5.1. Hospital Pharmacy

14.5.2. Retail Pharmacy

14.5.3. Online Pharmacy

14.6. Market Value Forecast, by Country/Sub-region, 2017-2031

14.6.1. GCC Countries

14.6.2. South Africa

14.6.3. Rest of Middle East & Africa

14.7. Market Attractiveness Analysis

14.7.1. By Drug Class

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

14.7.2. By Indication

14.7.3. By Distribution Channel

14.7.4. By Country/Sub-region

15. Competition Landscape

15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)

15.2. Market Share Analysis, by Company (2022)

15.3. Company Profiles

15.3.1. AstraZeneca

15.3.1.1. Company Overview

15.3.1.2. Product Portfolio

15.3.1.3. SWOT Analysis

15.3.1.4. Financial Overview

15.3.1.5. Strategic Overview

15.3.2. Pfizer Inc.

15.3.2.1. Company Overview

15.3.2.2. Product Portfolio

15.3.2.3. SWOT Analysis

15.3.2.4. Financial Overview

15.3.2.5. Strategic Overview

15.3.3. Novartis AG

15.3.3.1. Company Overview

15.3.3.2. Product Portfolio

15.3.3.3. SWOT Analysis

15.3.3.4. Financial Overview

15.3.3.5. Strategic Overview

15.3.4. Merck & Co. Inc.

15.3.4.1. Company Overview

15.3.4.2. Product Portfolio

15.3.4.3. SWOT Analysis

15.3.4.4. Financial Overview

15.3.4.5. Strategic Overview

15.3.5. Bristol-Myers Squibb Company

15.3.5.1. Company Overview

15.3.5.2. Product Portfolio

15.3.5.3. SWOT Analysis

15.3.5.4. Financial Overview

15.3.5.5. Strategic Overview

15.3.6. Bayer AG

15.3.6.1. Company Overview

15.3.6.2. Product Portfolio

15.3.6.3. SWOT Analysis

15.3.6.4. Financial Overview

15.3.6.5. Strategic Overview

15.3.7. Sanofi

15.3.7.1. Company Overview

15.3.7.2. Product Portfolio

15.3.7.3. SWOT Analysis

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15.3.7.4. Financial Overview
- 15.3.7.5. Strategic Overview
- 15.3.8. Boehringer Ingelheim GmbH
 - 15.3.8.1. Company Overview
 - 15.3.8.2. Product Portfolio
 - 15.3.8.3. SWOT Analysis
 - 15.3.8.4. Financial Overview
 - 15.3.8.5. Strategic Overview
- 15.3.9. F. Hoffmann-La Roche Ltd.
 - 15.3.9.1. Company Overview
 - 15.3.9.2. Product Portfolio
 - 15.3.9.3. SWOT Analysis
 - 15.3.9.4. Financial Overview
 - 15.3.9.5. Strategic Overview
- 15.3.10. Abbott Laboratories
 - 15.3.10.1. Company Overview
 - 15.3.10.2. Product Portfolio
 - 15.3.10.3. SWOT Analysis
 - 15.3.10.4. Financial Overview
 - 15.3.10.5. Strategic Overview
- 15.3.11. Gilead Sciences, Inc.
 - 15.3.11.1. Company Overview
 - 15.3.11.2. Product Portfolio
 - 15.3.11.3. SWOT Analysis
 - 15.3.11.4. Financial Overview
 - 15.3.11.5. Strategic Overview
- 15.3.12. Johnson & Johnson
 - 15.3.12.1. Company Overview
 - 15.3.12.2. Product Portfolio
 - 15.3.12.3. SWOT Analysis
 - 15.3.12.4. Financial Overview
 - 15.3.12.5. Strategic Overview
- 15.3.13. Astellas Pharma, Inc.
 - 15.3.13.1. Company Overview
 - 15.3.13.2. Product Portfolio
 - 15.3.13.3. SWOT Analysis
 - 15.3.13.4. Financial Overview
 - 15.3.13.5. Strategic Overview
- 15.3.14. Eli Lilly and Company
 - 15.3.14.1. Company Overview
 - 15.3.14.2. Product Portfolio
 - 15.3.14.3. SWOT Analysis
 - 15.3.14.4. Financial Overview
 - 15.3.14.5. Strategic Overview
- 15.3.15. Otsuka Holdings Co., Ltd.
 - 15.3.15.1. Company Overview
 - 15.3.15.2. Product Portfolio

15.3.15.3. SWOT Analysis

15.3.15.4. Financial Overview

15.3.15.5. Strategic Overview

15.3.16. Takeda Pharmaceuticals Company Ltd.

15.3.16.1. Company Overview

15.3.16.2. Product Portfolio

15.3.16.3. SWOT Analysis

15.3.16.4. Financial Overview

15.3.16.5. Strategic Overview

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Cardiovascular Drugs Market [Indication: Hypertension, Hyperlipidemia, Coronary Artery Disease, Peripheral Artery Disease, Arrhythmia, and Others; Distribution Channel: Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy] - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Market Report | 2023-12-28 | 241 pages | Transparency Market Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$5795.00
	Multi User License	\$8795.00
	Global Site License	\$11795.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784


tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Date

2026-02-20

Signature



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com